

# NTRK Fusions in NSCLC

Practice Changing in 2018 and Beyond? CME

**MONDAY, SEPTEMBER 24, 2018**

**TIME: 7:00 AM | REGISTRATION AND BREAKFAST: 6:30 AM**

**VENUE: METRO TORONTO CONVENTION CENTER (MTCC) NORTH BUILDING, 255 FRONT STREET WEST,  
TORONTO, ONTARIO M5V 2W6, CANADA**

**ROOM: 106**



Please visit:

[www.medscape.org/symposium/ntrk-nsclc-registration](http://www.medscape.org/symposium/ntrk-nsclc-registration)

## MODERATOR



**Ramaswamy Govindan, MD**  
Professor of Medicine  
Director of Medical Oncology  
Washington University School of Medicine  
St. Louis, Missouri

## FACULTY



**Trevor G. Bivona, MD, PhD**  
Associate Professor, Hematology and Oncology  
University of California San Francisco



**Alexander Drilon, MD**  
Assistant Attending Physician, Oncology  
Memorial Sloan Kettering Cancer Center  
New York, New York



**Luis E. Raez, MD**  
Clinical Professor of Medicine  
Florida International University  
Chief of Hematology/Oncology  
Medical Director  
Memorial Cancer Institute  
Pembroke Pines, Florida

## AGENDA

6:30 AM

*Registration & Breakfast*

7:00 AM

*Presentation*

*Welcome & Introductions*

Ramaswamy Govindan, MD

*A Case Example of Lung Cancer and NTRK Fusions: Making the Diagnosis*

Luis E. Raez, MD

*A Case Example of Lung Cancer and NTRK Fusions: Management*

Alexander Drilon, MD

*Sizing up Resistance: Getting in Front of the Problem*

Trever G. Bivona, MD, PhD

*Personalizing Therapy in Patients With NTRK Fusions: Will It Go the Way of EGFR?*

Ramaswamy Govindan, MD

7:55 AM

*Question & Answer*

## TARGET AUDIENCE

This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

## LEARNING OBJECTIVES

Upon completion of this activity, participants will:

Have increased knowledge regarding the

- Clinical trial data on the use of TRK inhibitors in management of patients with lung cancer that contains NTRK fusions
- Emerging data on how to combat TRK inhibitor resistance

Have greater competence related to

- Identifying which TRK inhibitors are likely to benefit patients with lung cancer
- Selecting the most appropriate regimen in a patient with lung cancer whose tumor harbors an NTRK fusion

## ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 **AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### DISCLAIMER

*This program was approved by the IASLC 19th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 19th World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC.*

Medscape



JOINTLY ACCREDITED PROVIDER<sup>™</sup>  
INTERPROFESSIONAL CONTINUING EDUCATION

Please visit:

[www.medscape.org/symposium/ntrk-nsclc-registration](http://www.medscape.org/symposium/ntrk-nsclc-registration)

Medscape  
Oncology

